Abstract:Chronic Myelogenous Leukemia (CML) is one of myeloproliferative disorders characterized by the chromosome translocation (9; 22), which causes the generation of the Bcr-Abl fusion protein. Latter activates a number of signal transducers and transcription factors, thus leading to multi-resistance to chemotherapeutic agents. Introduction of imatinib mesylate (Gleevec) significantly increased CML patients' response but still some of patients got disease progression. Therefore, it still remains a high priority to develop new approaches to treat Bcr-Abl+ leukemia. Aim: We aim to investigate the synergy of bortezomib and arsenic trioxide on inducing the apoptosis on Bcr-Abl+ K562-s as well as K562-r cells, which was sensitive or resistant to imatinib treatment respectively. Material and methods: Bcr-Abl+ K562-s and K562-r cells were chosen to evaluate the drugs' effect. We observed the inhibition of cell growth and cell viability after bortezomib and/or arsenic treatment. Flow cytometric evaluation and western blot analysis were performed to detect the development of apoptosis, the changeable expression of Bcr-Abl protein and the apoptosis-related proteins. Results: K562-s and K562-r cells had different response to imatinib treatment. As expected, 0.25μM of imatinib can inhibit half of K562-s cell growth whereas 10–15 more times of concentration of imatinib were necessary to reach the same inhibitory effect in K562-r cells. Combined bortezomib at 12nM with 1μM of ATO, the concentration inducing 50% of K562-s growth arrest, synergistically induced apoptosis in K562-s cells after 48hrs of cotreatment, confirmed by notable elevation of Annexin V+ cells through flow cytometric analysis, when compared to those in the control or single treatment (p<0.01), and immunoblotting detection of caspase-3 cleavage, degradation of poly-adenosine diphosphate-ribose polymerase (PARP), and decreased expression of Bcr-Abl protein. More surprisingly, 24nM concentration of bortezomib and 2μM of ATO, 2 times of concentration needed for 50% of K562-s cell growth inhibition respectively, inhibited 50% of K562-r cells growth, far less than the increased proportion needed during imatinib treatment. And more of important, although single treatment of bortezomib or ATO had no or little effect on inducing apoptosis, combined treatment significantly induced the apoptosis in K562-r cells (p<0.05), associated with activation of apoptosis-relevant proteins and obvious degradation of Bcr-Abl protein.

[Effect of Up-Regulated Expression of Tumor Suppressor Gene P14(arf) on Apoptosis of Chronic Myeloid Leukemia Cells].

Berbamine Exhibits Potent Antitumor Effects on Imatinib-Resistant CML Cells in Vitro and in Vivo

[Effect of Tyrosine-Kinase Inhibitor on P15 Gene Transfected K562 Cells].

Effects of overexpressing p14 ARF on the apoptosis in human melanoma cells irradiated with γ-ray

Effects Of Overexpressing P14(Arf) On The Apoptosis In Human Melanoma Cells Irradiated With Gamma-Ray

Effects of overexpressing<i>p14</i><sup>ARF</sup> on the apoptosis in human melanoma cells irradiated with γ-ray

Roles of Phosphorylated P210bcr/abl and Hsp90 Protein in Apoptosis Induced by Berbamine in K562 Cells.

Effect of p16 gene cloning combined with imatinib on chronic myeloid leukemia K562 cell line

[Effect of VE-cadherin on sensitivity to Imatinib in Sup-B15 Philadelphia chromosome positive acute lymphoblastic leukemia cells].

A Combination of STI571 and BCR-ABL1 Sirna with Overexpressed P15ink4b Induced Enhanced Proliferation Inhibition and Apoptosis in Chronic Myeloid Leukemia

P14arf Upregulation of P53 and Enhanced Effects of 5-Fluorouracil in Pancreatic Cancer.

[Effect of Csn-B Combined with Imatinib on Apoptosis of Chronic Myeloid Leukemia Cells through Nur77/Pim-1/Drp1 Pathway]

Apoptosis of Leukemic Cells Induced by Flavonoids of Puerarin and Its Molecular Mechanisms

Synergistically Cooperation of Bortezomib and Arsenic Trioxide on Chronic Myelogenous Leukemia

Effects of Gemcitabine on Proliferation, Apoptosis and Expression of Bcr/abl Fusion Gene Mrna in K562 Cells

Effect of CFTR on viability and apoptosis of acute leukemia cells and its related mechanisms

Coordination of Intrinsic, Extrinsic, and Endoplasmic Reticulum-Mediated Apoptosis by Imatinib Mesylate Combined with Arsenic Trioxide in Chronic Myeloid Leukemia.

Effects of Overexpressing P14~(arf) on the Proliferation in Human Melanoma Cells

The synergistic effect of miR-203 and cytarabine on the inhibition of cell proliferation and induction of apoptosis in chronic myelogenous leukemia cells

Effect of G-CSF on the Apoptosis Induced by Ara-c in HL-60 Leukemic Cells

[Effect of A Novel Emodin Derivative on Chronic Myelogenous Leukemia K562 Cells and Imatinib-resistant K562/G01 Cells].